Agents and Actions

, Volume 17, Issue 3–4, pp 371–372 | Cite as

Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba

  • C. Touvay
  • A. Etienne
  • P. Braquet
New Anti-inflammatory Agents

Abstract

Paf-acether appears to be a potent mediator released in response to allergen exposure in sensitized animals and it could contribute to clinical manifestations of allergic asthma. In order to ascertain this assumption the inhibition of antigen-induced lung anaphylaxis in guinea-pig by BN 52021, a new highly specific paf-acether antagonist, was studied. Ovalbumin injected into passively sensitized guinea-pig induced a large bronchoconstriction which was accompanied by thrombocytopenia and leukopenia. Treatment of animals with BN 52021 i.v., five minutes before challenge, strongly (at the doses of 1 and 2 mg/kg) or totally (at 0.1 mg/kg) inhibited the bronchoconstriction and partially reduced the thrombocytopenia and leukopenia the thrombocytopenia occurring after challenge. These results confirm that paf-acether and platelets might play a key role in asthma. BN 52021 and other paf-acether antagonist could provide a new group of potent prophylactic anti-asthma drugs.

Keywords

Asthma Receptor Antagonist Thrombocytopenia Clinical Manifestation Leukopenia 

References

  1. [1]
    B.B. Vargaftig, M. Chignard, J. Benveniste, J. Lefort andF. Wal,Background and present status of research on platelet activating factor (paf-acether), Ann. N.Y. Acad. Sci.370, 119–137 (1981).PubMedGoogle Scholar
  2. [2]
    J. Benveniste, P.M. Henson andC.G. Cochrane,Leukocyte-dependent histamine release from rabbit platelet. The role of IgE, basophils and platelet activating factor, J. Exp. Med.136, 1356–1377 (1972).Google Scholar
  3. [3]
    B.B. Vargaftig, J. Lefort, M. Chignard andJ. Benveniste,Platelet activating factor induced platelet dependent-bronchoconstriction unrelated to the formation of prostaglandin derivates, Eur. J. Pharmacol.65, 185–192 (1980).CrossRefPubMedGoogle Scholar
  4. [4]
    G.S. Basran, C.P. Page, W. Paul andJ. Morley,Platelet activating factor possible mediator of the dual response to allergen? Clin. Allergy.14, 75–79 (1984).PubMedGoogle Scholar
  5. [5]
    P.G. Braquet,Treatment and prevention of paf-acether-induced sickness by a new series of highly specific inhibitors, G.B. Patent 8, 418–424 (1984).Google Scholar
  6. [6]
    C. Touvay, B. Vilain, J.E. Taylor, A. Etienne, P.E. Chabrier andP. Braquet,Proof of the involvement of platelet activating factor (paf-acether) in pulmonary complex immune systems using a specific paf-acether receptor antagonist, BN 52021, Prog. Lipid Res., (in press).Google Scholar
  7. [7]
    J. Morley, S. Sanjar andC.P. Page,The platelet in asthma, Lancet, 1142–1144 (1984).Google Scholar

Copyright information

© Birkhäuser Verlag 1985

Authors and Affiliations

  • C. Touvay
    • 1
  • A. Etienne
    • 1
  • P. Braquet
    • 1
  1. 1.I.H.B.—IPSEN Institute for Therapeutic ResearchLe Plessis Robinson(France)

Personalised recommendations